Pharmaceutical firm Immunomedics reported favorable preclinical developments with a new antibody labeling method for use in breast cancer therapy. In results presented at this week's annual meeting of the Society of Nuclear Medicine, researchers evaluated humanized RS7, an antibody that targets breast, lung, prostate, and ovarian cancers, according to the Morris Plains, NJ-based firm.
In the study, hRS7 was labeled with iodine-131 using the company's method of improving the length of time I-131 stays attached to the antibody. With the new method, the firm achieved four times the dose of I-131 compared with conventional labeling methods, Immunomedics said. The increased exposure of I-131 to the tumor resulted in a 75% cure rate of the animals studied with transplanted human breast cancer, Immunomedics said.
By AuntMinnie.com staff writers
June 20, 2002
Related Reading
Immunomedics signs South American distributor, May 17, 2002
Immunomedics eyes Australia for LeukoScan, March 7, 2002
Immunomedics doubles revenue, trims loss, November 9, 2001
Immunomedics licenses labeling method, October 29, 2001
Immunomedics trims loss in 2001, August 8, 2001
Copyright © 2002 AuntMinnie.com
